<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="147998">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01918787</url>
  </required_header>
  <id_info>
    <org_study_id>100-2985C</org_study_id>
    <secondary_id>NSC 100-2314-B-182A-075</secondary_id>
    <nct_id>NCT01918787</nct_id>
  </id_info>
  <brief_title>rTMS for Adults With Autistic Spectrum Disorder</brief_title>
  <official_title>Examine the Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) Over the Symptoms of Autism Spectrum Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Chang Gung Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Chang Gung Memorial Hospital</source>
  <oversight_info>
    <authority>Taiwan: Department of Health</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      rTMS over dorsolateral prefrontal cortex is effective in reducing repetitive behaviors in
      adults with autistic spectrum disorder rTMS over posterior superior temporal sulcus is
      effective in improving social ability in adults with autistic spectrum disorder
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      First, we will apply one session intermittent theta burst stimulation over dorsolateral
      prefrontal cortex, posterior superior temporal sulcus and inion as control with one week
      interval in adults with autism spectrum disorder. Second, we will apply 5 sessions
      intermittent theta burst stimulation within one week over dorsolateral prefrontal cortex or
      posterior temporal sulcus depending on the results of our first phases.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Anticipated">April 2015</completion_date>
  <primary_completion_date type="Anticipated">April 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>continuous performance test</measure>
    <time_frame>continuous performance test will be arranged before and after rTMS within one hour</time_frame>
    <safety_issue>No</safety_issue>
    <description>continuous performance test will be arranged before and after rTMS within one hour</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Yale-Brown Obsessive Compulsive Scale</measure>
    <time_frame>Yale-Brown Obsessive Compulsive Scale will be evaluated before and after rTMS within one week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Yale-Brown Obsessive Compulsive Scale will be evaluated before and after rTMS. The time point of evaluation is before rTMS, one hour after rTMS, 3 days after rTMS and one week after rTMS.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Autism Spectrum Quotient</measure>
    <time_frame>Autism Spectrum Quotient will be evaluated before and after rTMS within one week</time_frame>
    <safety_issue>No</safety_issue>
    <description>Autism Spectrum Quotient will be evaluated before and after rTMS. The time point of evaluation is before rTMS, one hour after rTMS, 3 days after rTMS and one week after rTMS.</description>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Autism</condition>
  <arm_group>
    <arm_group_label>repetitive TMS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>repetitive TMS over dorsolateral prefrontal cortex, posterior superior temporal sulcus and inion as control</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>repetitive TMS</intervention_name>
    <description>rTMS (intermittent theta burst stimulation 1200)over posterior superior temporal sulcus,dorsolateral prefrontal cortex and inion as Sham control</description>
    <arm_group_label>repetitive TMS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  adults with autistic spectrum disorder

        Exclusion Criteria:

          -  schizophrenia

          -  bipolar affective disorder

          -  major depressive disorder

          -  any systemic disease especially epilepsy
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hsing-Chang Ni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Chang Gung Memorial Hospital at Linkou, Taiwan</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Hsing Chang Ni, MD</last_name>
    <phone>886-3-3281200</phone>
    <phone_ext>2479</phone_ext>
    <email>alanni0918@yahoo.com.tw</email>
  </overall_contact>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital</name>
      <address>
        <city>Taoyuan</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hsing Chang Ni</last_name>
      <phone>886-3-3281200</phone>
      <phone_ext>2479</phone_ext>
      <email>alanni0918@yahoo.com.tw</email>
    </contact>
    <investigator>
      <last_name>Hsing Chang Ni, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>April 2012</verification_date>
  <lastchanged_date>August 7, 2013</lastchanged_date>
  <firstreceived_date>August 2, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Autistic Disorder</mesh_term>
    <mesh_term>Child Development Disorders, Pervasive</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
